Suzetrigine (brand name Journavx) is a first-in-class, non-opioid medication approved for the treatment of moderate-to-severe acute pain in adults.
A first-in-class, oral, non-opioid, highly selective pain signal inhibitor…
Mechanism of Action: It is a selective NaV1.8 sodium channel blocker.
Unlike opioids, which act on the central nervous system, suzetrigine blocks pain signals in the peripheral nervous system before they reach the brain.
Non-Addictive: Because it does not target the brain’s reward system, it carries no risk of addiction, physical dependence, or opioid-related side effects like respiratory depression.
Usage: It is administered as a 50 mg oral tablet twice daily (every 12 hours). It is intended for short-term use, generally not exceeding 14 days.
Indication: moderate-to-severe acute pain in adults
Adverse profile headache and constipation most common; no clinically significant QTc prolongation at 2× max exposure.
Common Side Effects: These include itching (pruritus), muscle spasms, skin rash, and increased levels of creatine phosphokinase (CPK).
Cost: The wholesale acquisition cost is approximately $15.50 per pill.
Contraindications: Avoid use with strong CYP3A inhibitors (e.g., erythromycin, ketoconazole) or inducers (e.g., St. John’s Wort).
Do not consume grapefruit or grapefruit juice while taking this medication.
Not recommended for patients with severe liver impairment (Child-Pugh C).
Reproductive Health: Suzetrigine may decrease the effectiveness of hormonal contraceptives and may temporarily cause infertility in women.